Patents Assigned to Bellus Health (International) Limited
-
Publication number: 20110002875Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: January 6, 2011Applicant: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter Szarek, Donald Weaver
-
Patent number: 7786174Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 22, 2008Date of Patent: August 31, 2010Assignee: Bellus Health (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20100190753Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: ApplicationFiled: August 27, 2009Publication date: July 29, 2010Applicant: BELLUS Health (International) LimitedInventors: Xianqi KONG, Walter A. Szarek, Francine Gervais
-
Patent number: 7754761Abstract: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.Type: GrantFiled: February 16, 2007Date of Patent: July 13, 2010Assignee: Bellus Health (International) LimitedInventors: Robert Kisilevsky, Walter A. Szarek, Donald F. Weaver
-
Publication number: 20100113591Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: November 5, 2009Publication date: May 6, 2010Applicant: BELLUS Health (International) LimitedInventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
-
Patent number: 7598269Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.Type: GrantFiled: May 30, 2007Date of Patent: October 6, 2009Assignee: Bellus Health (International) LimitedInventors: Xianqi Kong, Walter A. Szarek, Francine Gervais
-
Publication number: 20090099100Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C?O), thiocarbonyl (C?S), sulfonyl (SO2), or sulfoxide (S?O) group. “k” and “m” are 0 or 1, provided when k is 1, R1 is not a hydrogen atom, and when m is 1, R2 is not a hydrogen atom. In an embodiment, at least one of k or m must equal 1. “p” and “s” are each independently positive integers selected such that the biodistribution of the therapeutic compound for an intended target site is not prevented while maintaining activity of the therapeutic compound.Type: ApplicationFiled: July 7, 2008Publication date: April 16, 2009Applicant: Bellus Health (International) LimitedInventors: Walter Szarek, Donald Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20080249184Abstract: The invention provides methods of inhibiting A?-induced neuronal cell death. The invention further provides methods of providing neuroprotection to a subject and methods of treating a disease state characterized by A?-induced neuronal cell death in a subject. Methods of inhibiting p75 receptor mediated neuronal cell death, as well as methods of treating a disease state in a subject characterized by p75 receptor mediated neuronal cell death are provided.Type: ApplicationFiled: June 9, 2008Publication date: October 9, 2008Applicant: Bellus Health (International) LimitedInventors: Francine Gervais, Louis R. Lamontagne